NCT01109264 - Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia | Biotech Hunter

Enrollment

147

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

June 30, 2013

Study Completion Date

August 31, 2013

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

Bendamustine hydrochloride injection

d1-2, i.v.gtt, 100mg/m2, 28 days per cycle, at most 6 cycles

DRUG

Chlorambucil

d1-d2, d15-d16, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles

Trial Locations (1)

Ruijin Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai